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This supplement was created to provide transparent
documentation and access to the planning phase of
the largest, multi-site etiological study for childhood
pneumonia being undertaken since the Board of
Science and Technology for International Development
(BOSTID) studies were done in the 1980s [1]. The
Pneumonia Etiology Research for Child Health (PERCH)
study will use a case-control design to characterize the
etiologic distribution of pathogens that are causing
severe pneumonia among children under 5 years
of age who have been hospitalized for their illness
in seven countries in Africa and Asia (Africa: Basse,
Gambia; Kilifi, Kenya; Bamako, Mali; Soweto, South
Africa; Lusaka, Zambia. Asia: Kamlapur and Matlab,
Bangladesh, Sao Kaeo and Nakhon Phanom, Thailand).
A large number of individuals and institutions have
provided input, guidance, advice, literature reviews,
and materials that have contributed to the study de-
sign and procedures. A specific goal of the study was
to assure that the processes, information and decisions
are made fully available to other researchers in order
to leverage the lessons garnered from the develop-
ment of the PERCH protocol for the greatest possible
impact.
The PERCH project is coordinated by a core team
of individuals who have expertise in epidemiology,
clinical medicine, statistics, laboratory diagnostics and
study conduct; the PERCH Core team is comprised of
individuals from the Johns Hopkins Bloomberg School
of Public Health, the University of Otago and the
Oxford University/KEMRI Wellcome Trust.
The PERCH Core team commissioned a Pneumonia
Methods Working Group (PMWG), which consists of
16 external experts in these domains. The PMWG pro-
vided critical, consensus-driven advice on 90 clinical,
laboratory and epidemiologic design issues that were
difficult to resolve. Issues have been referred to the
PMWG for which alternate approaches would mean-
ingfully impact the study results and for which con-
troversy or lack of consensus existed on the optimal
approach. The process and content of the PMWG
work is described further by Levine et al [2].
The site selection was carried out by a request for
proposals, with 52 applicants responding to the request.
A Site Selection Committee, external and independent
of the PERCH Core team, was charged with reviewing
the applications and providing a score for each appli-
cant. These were reviewed during an in-person meeting
of the Site Selection Committee, and the short list was
reviewed for strategic areas of focus by the PERCH
Core team and the study sponsor, The Bill & Melinda
Gates Foundation.
The papers in this supplement aim to address the
rationale behind the epidemiologic, clinical, labora-
tory and statistical design components of the PERCH
study. The papers describe the output of this process,
with some presenting the key decision points and jus-
tifications for certain elements of the study design,
and others describing the background documentation
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and literature review that formed the basis of these decisions. In
addition, this supplement offers several papers that address
ancillary issues to the main study, such as the bioethics of
conducting pneumonia research in developing countries and
an approach to post-mortem specimen collection. Lastly, the
supplement contains two papers describing pilot etiological
childhood pneumonia studies that were undertaken in Kenya
and New Caledonia, which provided data to design the larger
PERCH study. In addition to this supplement, additional
documentation can be found in the full set of PMWG docu-
ments and the PERCH protocol, which are freely available for
consultation and consideration (http://www.jhsph.edu/ivac/
perch.html).
The decisions reached and incorporated into the PERCH
study design are not the only ones that could have been
reached, as in some cases, the decisions were based on expert
opinion rather than firm data. We offer these papers as
a means to share with those who were not present during
the process and deliberations, and for those who were in-
volved, a set of written documents that reflects the process
and deliberations undertaken. Designing epidemiologic
studies inherently requires some degree of subjective de-
cision making, and we do not necessarily believe all future
pneumonia etiology studies should strictly follow the
PERCH methodology. However, the process of decision
making for PERCH was rigorous, deliberative and inclusive and
took 18 months to complete. We hope that these efforts can
benefit other researchers and result in a greater degree of-
standardization in the field of childhood pneumonia research.
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